Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6011 in RA Inadequately Responding to Biologics
NCT02960490Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2016
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of quetmolimab in rheumatoid arthritis (RA) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: American College of Rheumatology 20 Response at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
quetmolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02960490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960490.